510 related articles for article (PubMed ID: 15122511)
1. CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies.
CHEK2 Breast Cancer Case-Control Consortium
Am J Hum Genet; 2004 Jun; 74(6):1175-82. PubMed ID: 15122511
[TBL] [Abstract][Full Text] [Related]
2. Excess breast cancer risk in first degree relatives of CHEK2∗1100delC positive familial breast cancer cases.
Adank MA; Verhoef S; Oldenburg RA; Schmidt MK; Hooning MJ; Martens JW; Broeks A; Rookus M; Waisfisz Q; Witte BI; Jonker MA; Meijers-Heijboer H
Eur J Cancer; 2013 May; 49(8):1993-9. PubMed ID: 23415889
[TBL] [Abstract][Full Text] [Related]
3. CHEK2 1100delC is a susceptibility allele for HNPCC-related colorectal cancer.
Wasielewski M; Vasen H; Wijnen J; Hooning M; Dooijes D; Tops C; Klijn JG; Meijers-Heijboer H; Schutte M
Clin Cancer Res; 2008 Aug; 14(15):4989-94. PubMed ID: 18676774
[TBL] [Abstract][Full Text] [Related]
4. Family history, genetic testing, and clinical risk prediction: pooled analysis of CHEK2 1100delC in 1,828 bilateral breast cancers and 7,030 controls.
Fletcher O; Johnson N; Dos Santos Silva I; Kilpivaara O; Aittomäki K; Blomqvist C; Nevanlinna H; Wasielewski M; Meijers-Heijerboer H; Broeks A; Schmidt MK; Van't Veer LJ; Bremer M; Dörk T; Chekmariova EV; Sokolenko AP; Imyanitov EN; Hamann U; Rashid MU; Brauch H; Justenhoven C; Ashworth A; Peto J
Cancer Epidemiol Biomarkers Prev; 2009 Jan; 18(1):230-4. PubMed ID: 19124502
[TBL] [Abstract][Full Text] [Related]
5. CHEK2 1100delC variant and breast cancer risk in Caucasians: a meta-analysis based on 25 studies with 29,154 cases and 37,064 controls.
Yang Y; Zhang F; Wang Y; Liu SC
Asian Pac J Cancer Prev; 2012; 13(7):3501-5. PubMed ID: 22994785
[TBL] [Abstract][Full Text] [Related]
6. Age- and Tumor Subtype-Specific Breast Cancer Risk Estimates for CHEK2*1100delC Carriers.
Schmidt MK; Hogervorst F; van Hien R; Cornelissen S; Broeks A; Adank MA; Meijers H; Waisfisz Q; Hollestelle A; Schutte M; van den Ouweland A; Hooning M; Andrulis IL; Anton-Culver H; Antonenkova NN; Antoniou AC; Arndt V; Bermisheva M; Bogdanova NV; Bolla MK; Brauch H; Brenner H; Brüning T; Burwinkel B; Chang-Claude J; Chenevix-Trench G; Couch FJ; Cox A; Cross SS; Czene K; Dunning AM; Fasching PA; Figueroa J; Fletcher O; Flyger H; Galle E; García-Closas M; Giles GG; Haeberle L; Hall P; Hillemanns P; Hopper JL; Jakubowska A; John EM; Jones M; Khusnutdinova E; Knight JA; Kosma VM; Kristensen V; Lee A; Lindblom A; Lubinski J; Mannermaa A; Margolin S; Meindl A; Milne RL; Muranen TA; Newcomb PA; Offit K; Park-Simon TW; Peto J; Pharoah PD; Robson M; Rudolph A; Sawyer EJ; Schmutzler RK; Seynaeve C; Soens J; Southey MC; Spurdle AB; Surowy H; Swerdlow A; Tollenaar RA; Tomlinson I; Trentham-Dietz A; Vachon C; Wang Q; Whittemore AS; Ziogas A; van der Kolk L; Nevanlinna H; Dörk T; Bojesen S; Easton DF
J Clin Oncol; 2016 Aug; 34(23):2750-60. PubMed ID: 27269948
[TBL] [Abstract][Full Text] [Related]
7. CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls.
Weischer M; Bojesen SE; Ellervik C; Tybjaerg-Hansen A; Nordestgaard BG
J Clin Oncol; 2008 Feb; 26(4):542-8. PubMed ID: 18172190
[TBL] [Abstract][Full Text] [Related]
8. The CHEK2*1100delC allelic variant and risk of breast cancer: screening results from the Breast Cancer Family Registry.
Bernstein JL; Teraoka SN; John EM; Andrulis IL; Knight JA; Lapinski R; Olson ER; Wolitzer AL; Seminara D; Whittemore AS; Concannon P
Cancer Epidemiol Biomarkers Prev; 2006 Feb; 15(2):348-52. PubMed ID: 16492927
[TBL] [Abstract][Full Text] [Related]
9. Increased Risk for Other Cancers in Addition to Breast Cancer for CHEK2*1100delC Heterozygotes Estimated From the Copenhagen General Population Study.
Näslund-Koch C; Nordestgaard BG; Bojesen SE
J Clin Oncol; 2016 Apr; 34(11):1208-16. PubMed ID: 26884562
[TBL] [Abstract][Full Text] [Related]
10. Absence of CHEK2*1100delC mutation in families with hereditary breast cancer in North America.
Iniesta MD; Gorin MA; Chien LC; Thomas SM; Milliron KJ; Douglas JA; Merajver SD
Cancer Genet Cytogenet; 2010 Oct; 202(2):136-40. PubMed ID: 20875877
[TBL] [Abstract][Full Text] [Related]
11. Interaction between CHEK2*1100delC and other low-penetrance breast-cancer susceptibility genes: a familial study.
Johnson N; Fletcher O; Naceur-Lombardelli C; dos Santos Silva I; Ashworth A; Peto J
Lancet; 2005 Oct 29-Nov 4; 366(9496):1554-7. PubMed ID: 16257342
[TBL] [Abstract][Full Text] [Related]
12. Chromosomal radiosensitivity of breast cancer with a CHEK2 mutation.
Baeyens A; Claes K; Willems P; De Ruyck K; Thierens H; Vral A
Cancer Genet Cytogenet; 2005 Dec; 163(2):106-12. PubMed ID: 16337852
[TBL] [Abstract][Full Text] [Related]
13. Frequency of CHEK2 mutations in a population based, case-control study of breast cancer in young women.
Friedrichsen DM; Malone KE; Doody DR; Daling JR; Ostrander EA
Breast Cancer Res; 2004; 6(6):R629-35. PubMed ID: 15535844
[TBL] [Abstract][Full Text] [Related]
14. The CHEK2*1100delC variant acts as a breast cancer risk modifier in non-BRCA1/BRCA2 multiple-case families.
Oldenburg RA; Kroeze-Jansema K; Kraan J; Morreau H; Klijn JG; Hoogerbrugge N; Ligtenberg MJ; van Asperen CJ; Vasen HF; Meijers C; Meijers-Heijboer H; de Bock TH; Cornelisse CJ; Devilee P
Cancer Res; 2003 Dec; 63(23):8153-7. PubMed ID: 14678969
[TBL] [Abstract][Full Text] [Related]
15. Increased risk of breast cancer associated with CHEK2*1100delC.
Weischer M; Bojesen SE; Tybjaerg-Hansen A; Axelsson CK; Nordestgaard BG
J Clin Oncol; 2007 Jan; 25(1):57-63. PubMed ID: 16880452
[TBL] [Abstract][Full Text] [Related]
16. A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer.
Vahteristo P; Bartkova J; Eerola H; Syrjäkoski K; Ojala S; Kilpivaara O; Tamminen A; Kononen J; Aittomäki K; Heikkilä P; Holli K; Blomqvist C; Bartek J; Kallioniemi OP; Nevanlinna H
Am J Hum Genet; 2002 Aug; 71(2):432-8. PubMed ID: 12094328
[TBL] [Abstract][Full Text] [Related]
17. Frequency of CHEK2*1100delC in New York breast cancer cases and controls.
Offit K; Pierce H; Kirchhoff T; Kolachana P; Rapaport B; Gregersen P; Johnson S; Yossepowitch O; Huang H; Satagopan J; Robson M; Scheuer L; Nafa K; Ellis N
BMC Med Genet; 2003 Jan; 4():1. PubMed ID: 12529183
[TBL] [Abstract][Full Text] [Related]
18. CHEK2*1100delC homozygosity is associated with a high breast cancer risk in women.
Adank MA; Jonker MA; Kluijt I; van Mil SE; Oldenburg RA; Mooi WJ; Hogervorst FB; van den Ouweland AM; Gille JJ; Schmidt MK; van der Vaart AW; Meijers-Heijboer H; Waisfisz Q
J Med Genet; 2011 Dec; 48(12):860-3. PubMed ID: 22058428
[TBL] [Abstract][Full Text] [Related]
19. CHEK2 1100delC is not a risk factor for male breast cancer population.
Syrjäkoski K; Kuukasjärvi T; Auvinen A; Kallioniemi OP
Int J Cancer; 2004 Jan; 108(3):475-6. PubMed ID: 14648717
[TBL] [Abstract][Full Text] [Related]
20. Genetic modifiers of CHEK2*1100delC-associated breast cancer risk.
Muranen TA; Greco D; Blomqvist C; Aittomäki K; Khan S; Hogervorst F; Verhoef S; Pharoah PDP; Dunning AM; Shah M; Luben R; Bojesen SE; Nordestgaard BG; Schoemaker M; Swerdlow A; García-Closas M; Figueroa J; Dörk T; Bogdanova NV; Hall P; Li J; Khusnutdinova E; Bermisheva M; Kristensen V; Borresen-Dale AL; ; Peto J; Dos Santos Silva I; Couch FJ; Olson JE; Hillemans P; Park-Simon TW; Brauch H; Hamann U; Burwinkel B; Marme F; Meindl A; Schmutzler RK; Cox A; Cross SS; Sawyer EJ; Tomlinson I; Lambrechts D; Moisse M; Lindblom A; Margolin S; Hollestelle A; Martens JWM; Fasching PA; Beckmann MW; Andrulis IL; Knight JA; ; Anton-Culver H; Ziogas A; Giles GG; Milne RL; Brenner H; Arndt V; Mannermaa A; Kosma VM; Chang-Claude J; Rudolph A; Devilee P; Seynaeve C; Hopper JL; Southey MC; John EM; Whittemore AS; Bolla MK; Wang Q; Michailidou K; Dennis J; Easton DF; Schmidt MK; Nevanlinna H
Genet Med; 2017 May; 19(5):599-603. PubMed ID: 27711073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
